Epix Medical MS-325 Imaging Agent NDA Filing Targeted For Early 2003
This article was originally published in The Gray Sheet
Executive Summary
Initial results from one of Epix Medical's four Phase III trials of the magnetic resonance imaging intravascular contrast agent MS-325 will be released at the upcoming American College of Cardiology annual meeting, March 17-20 in Atlanta